Search results
Results from the WOW.Com Content Network
Chronic spontaneous urticaria (CSU) also known as Chronic idiopathic urticaria (CIU) is defined by the presence of wheals, angioedema, or both for more than six weeks.The most common symptoms of chronic spontaneous urticaria are angioedema and hives that are accompanied by itchiness.
Hives including chronic spontaneous hives can be a complication and symptom of a parasitic infection, such as blastocystosis and strongyloidiasis among others. [ 11 ] The rash that develops from poison ivy , poison oak , and poison sumac contact is commonly mistaken for urticaria.
However, the understanding of urticaria as an autoimmune condition is a relatively recent development in medical history. [14] The term autoimmune urticaria refers to a subset of chronic spontaneous urticaria (CSU) cases where the immune system appears to play a significant role. This understanding began to evolve in the mid to late 20th ...
Dermatographic urticaria is sometimes called "skin writing", as it is possible to mark deliberate patterns onto the skin. The condition manifests as an allergic-like reaction, causing a warm red wheal to appear on the skin. As it is often the result of scratches, involving contact with other materials, it can be confused with an allergic ...
Urticaria is a vascular reaction of the skin characterized by the appearance of wheals. Angioedema , which can occur alone or with urticaria, is characterized by a well-defined, edematous swelling that involves subcutaneous tissues, abdominal organs, and/or upper airway.
Urticarial vasculitis (also known as "chronic urticaria as a manifestation of venulitis", "hypocomplementemic urticarial vasculitis syndrome", "hypocomplementemic vasculitis" and "unusual lupus-like syndrome") [1] is a skin condition characterized by fixed urticarial lesions that appear histologically as a vasculitis.
This cutaneous condition article is a stub. You can help Wikipedia by expanding it.
Xolair has been approved in many countries for treating severe, persistent allergic asthma. It has also been approved in March 2014 in the European Union [36] and the U. S. [37] for treating chronic spontaneous urticaria, which cannot be adequately treated with H1-antihistamines. In the second approach, antibodies specific for a domain of 52 ...